Semin Respir Crit Care Med 2011; 32(6): 717-726
DOI: 10.1055/s-0031-1295719
© Thieme Medical Publishers

Antifungal Prophylaxis in Lung Transplantation

Robin K. Avery1
  • 1Department of Infectious Disease, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio
Further Information

Publication History

Publication Date:
13 December 2011 (online)

ABSTRACT

Fungal infections are among the most serious complications of lung transplantation. The 1-year cumulative incidence of invasive fungal infections in lung transplant recipients is 6 to 10%, which is higher than most other solid organ transplant recipients. Aspergillus spp. are the most common etiologic agents, but Candida spp., non-Aspergillus mycelial fungi, Cryptococcus, Pneumocystis, and endemic mycoses can cause active infections in this population. Clinical manifestations of fungal infection in lung transplant recipients are protean, and include invasive pulmonary disease, airway and anastomotic infections, posttransplant empyemas, and disseminated infections. Most centers employ either universal or targeted antifungal prophylaxis in some form, but the agents, doses, durations, and monitoring strategies vary widely from one center to another. This review discusses the salient fungal organisms responsible for infection in lung transplant recipients and management strategies for prevention.

REFERENCES

  • 1 Singh N, Husain S. AST Infectious Diseases Community of Practice . Invasive aspergillosis in solid organ transplant recipients.  Am J Transplant. 2009;  9 (Suppl 4) S180-S191
  • 2 Husain S, Paterson D L, Studer S et al.. Voriconazole prophylaxis in lung transplant recipients.  Am J Transplant. 2006;  6 (12) 3008-3016
  • 3 Husain S, Mooney M L, Danziger-Isakov L et al.. A 2010 working formulation for the standardization of definitions of infections in cardiothoracic transplant recipients.  J Heart Lung Transplant. 2011;  30 (4) 361-374
  • 4 Kubak B M. Fungal infection in lung transplantation.  Transpl Infect Dis. 2002;  4 (Suppl 3) 24-31
  • 5 Danziger-Isakov L A, Worley S, Arrigain S et al.. Increased mortality after pulmonary fungal infection within the first year after pediatric lung transplantation.  J Heart Lung Transplant. 2008;  27 (6) 655-661
  • 6 Pappas P G, Alexander B D, Andes D R et al.. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET).  Clin Infect Dis. 2010;  50 (8) 1101-1111
  • 7 Husain S, Zaldonis D, Kusne S, Kwak E J, Paterson D L, McCurry K R. Variation in antifungal prophylaxis strategies in lung transplantation.  Transpl Infect Dis. 2006;  8 (4) 213-218
  • 8 Neoh C F, Snell G I, Kotsimbos T et al.. Antifungal prophylaxis in lung transplantation—a world-wide survey.  Am J Transplant. 2011;  11 (2) 361-366
  • 9 Singh N, Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management.  J Heart Lung Transplant. 2003;  22 (3) 258-266
  • 10 Husni R N, Gordon S M, Longworth D L et al.. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients.  Clin Infect Dis. 1998;  26 (3) 753-755
  • 11 Cahill B C, Hibbs J R, Savik K et al.. Aspergillus airway colonization and invasive disease after lung transplantation.  Chest. 1997;  112 (5) 1160-1164
  • 12 Flume P A, Egan T M, Paradowski L J, Detterbeck F C, Thompson J T, Yankaskas J R. Infectious complications of lung transplantation. Impact of cystic fibrosis.  Am J Respir Crit Care Med. 1994;  149 (6) 1601-1607
  • 13 Husain S. Unique characteristics of fungal infections in lung transplant recipients.  Clin Chest Med. 2009;  30 (2) 307-313, vii
  • 14 Choong C K, Sweet S C, Zoole J B et al.. Bronchial airway anastomotic complications after pediatric lung transplantation: incidence, cause, management, and outcome.  J Thorac Cardiovasc Surg. 2006;  131 (1) 198-203
  • 15 Cuellar-Rodriguez J, Avery R K, Lard M et al.. Histoplasmosis in solid organ transplant recipients: 10 years of experience at a large transplant center in an endemic area.  Clin Infect Dis. 2009;  49 (5) 710-716
  • 16 Hadjiliadis D, Sporn T A, Perfect J R, Tapson V F, Davis R D, Palmer S M. Outcome of lung transplantation in patients with mycetomas.  Chest. 2002;  121 (1) 128-134
  • 17 Weigt S S, Elashoff R M, Huang C et al.. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome.  Am J Transplant. 2009;  9 (8) 1903-1911
  • 18 Estenne M, Maurer J R, Boehler A et al.. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria.  J Heart Lung Transplant. 2002;  21 (3) 297-310
  • 19 Valentine V G, Gupta M R, Walker Jr J E et al.. Effect of etiology and timing of respiratory tract infections on development of bronchiolitis obliterans syndrome.  J Heart Lung Transplant. 2009;  28 (2) 163-169
  • 20 Valentine V G, Bonvillain R W, Gupta M R et al.. Infections in lung allograft recipients: ganciclovir era.  J Heart Lung Transplant. 2008;  27 (5) 528-535
  • 21 Liu M, Worley S, Mallory Jr G B et al.. Fungal infections in pediatric lung transplant recipients: colonization and invasive disease.  J Heart Lung Transplant. 2009;  28 (11) 1226-1230
  • 22 Luong M L, Morrissey O, Husain S. Assessment of infection risks prior to lung transplantation.  Curr Opin Infect Dis. 2010;  23 (6) 578-583
  • 23 Issa N C, Fishman J A. Infectious complications of antilymphocyte therapies in solid organ transplantation.  Clin Infect Dis. 2009;  48 (6) 772-786
  • 24 Peddi V R, Hariharan S, Schroeder T J, First M R. Role of granulocyte colony stimulating factor (G-CSF) in reversing neutropenia in renal allograft recipients.  Clin Transplant. 1996;  10 (1 Pt 1) 20-23
  • 25 Palmer S M, Limaye A P, Banks M et al.. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial.  Ann Intern Med. 2010;  152 (12) 761-769
  • 26 Goldfarb N S, Avery R K, Goormastic M et al.. Hypogammaglobulinemia in lung transplant recipients.  Transplantation. 2001;  71 (2) 242-246
  • 27 Jordan S C, Toyoda M, Kahwaji J, Vo A A. Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients.  Am J Transplant. 2011;  11 (2) 196-202
  • 28 Husain S, Raza K, Pilewski J M et al.. Experience with immune monitoring in lung transplant recipients: correlation of low immune function with infection.  Transplantation. 2009;  87 (12) 1852-1857
  • 29 Kanj S S, Tapson V, Davis R D, Madden J, Browning I. Infections in patients with cystic fibrosis following lung transplantation.  Chest. 1997;  112 (4) 924-930
  • 30 Gordon S M, LaRosa S P, Kalmadi S et al.. Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued?.  Clin Infect Dis. 1999;  28 (2) 240-246
  • 31 Palmer S M, Perfect J R, Howell D N et al.. Candidal anastomotic infection in lung transplant recipients: successful treatment with a combination of systemic and inhaled antifungal agents.  J Heart Lung Transplant. 1998;  17 (10) 1029-1033
  • 32 Hadjiliadis D, Howell D N, Davis R D et al.. Anastomotic infections in lung transplant recipients.  Ann Transplant. 2000;  5 (3) 13-19
  • 33 Horvath J, Dummer S, Loyd J, Walker B, Merrill W H, Frist W H. Infection in the transplanted and native lung after single lung transplantation.  Chest. 1993;  104 (3) 681-685
  • 34 Dowling R D, Baladi N, Zenati M et al.. Disruption of the aortic anastomosis after heart-lung transplantation.  Ann Thorac Surg. 1990;  49 (1) 118-122
  • 35 Hamacher J, Spiliopoulos A, Kurt A M, Nicod L P. Geneva Lung Transplantation Group . Pre-emptive therapy with azoles in lung transplant patients.  Eur Respir J. 1999;  13 (1) 180-186
  • 36 Minari A, Husni R, Avery R K et al.. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants.  Transpl Infect Dis. 2002;  4 (4) 195-200
  • 37 Hosseini-Moghaddam S M, Husain S. Fungi and molds following lung transplantation.  Semin Respir Crit Care Med. 2010;  31 (2) 222-233
  • 38 Husain S, Alexander B D, Munoz P et al.. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi.  Clin Infect Dis. 2003;  37 (2) 221-229
  • 39 Costa S F, Alexander B D. Non-Aspergillus fungal pneumonia in transplant recipients.  Clin Chest Med. 2005;  26 (4) 675-690, vii
  • 40 Sahi H, Avery R K, Minai O A et al.. Scedosporium apiospermum (Pseudoallescheria boydii) infection in lung transplant recipients.  J Heart Lung Transplant. 2007;  26 (4) 350-356
  • 41 Das A, MacLaughlin E F, Ross L A et al.. Paecilomyces variotii in a pediatric patient with lung transplantation.  Pediatr Transplant. 2000;  4 (4) 328-332
  • 42 Lee J, Yew W W, Chiu C S, Wong P C, Wong C F, Wang E P. Delayed sternotomy wound infection due to Paecilomyces variotii in a lung transplant recipient.  J Heart Lung Transplant. 2002;  21 (10) 1131-1134
  • 43 Tamm M, Malouf M, Glanville A. Pulmonary scedosporium infection following lung transplantation.  Transpl Infect Dis. 2001;  3 (4) 189-194
  • 44 Ambrosioni J, Bouchuiguir-Wafa K, Garbino J. Emerging invasive zygomycosis in a tertiary care center: epidemiology and associated risk factors.  Int J Infect Dis. 2010 14 (Suppl 3) e100-103
  • 45 Silveira F P, Kwak E J, Paterson D L, Pilewski J M, McCurry K R, Husain S. Post-transplant colonization with non-Aspergillus molds and risk of development of invasive fungal disease in lung transplant recipients.  J Heart Lung Transplant. 2008;  27 (8) 850-855
  • 46 Singh N, Forrest G. AST Infectious Diseases Community of Practice . Cryptococcosis in solid organ transplant recipients.  Am J Transplant. 2009;  9 (Suppl 4) S192-S198
  • 47 Singh N, Alexander B D, Lortholary O et al.. Pulmonary cryptococcosis in solid organ transplant recipients: clinical relevance of serum cryptococcal antigen.  Clin Infect Dis. 2008;  46 (2) e12-e18
  • 48 Singh N, Lortholary O, Alexander B D Cryptococcal Collaborative Transplant Study Group et al. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients.  Clin Infect Dis. 2005;  40 (12) 1756-1761
  • 49 Kontoyiannis D P, Lewis R E, Alexander B D et al.. Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis.  Antimicrob Agents Chemother. 2008;  52 (2) 735-738
  • 50 Miller M B, Hendren R, Gilligan P H. Posttransplantation disseminated coccidioidomycosis acquired from donor lungs.  J Clin Microbiol. 2004;  42 (5) 2347-2349
  • 51 Tripathy U, Yung G L, Kriett J M, Thistlethwaite P A, Kapelanski D P, Jamieson S W. Donor transfer of pulmonary coccidioidomycosis in lung transplantation.  Ann Thorac Surg. 2002;  73 (1) 306-308
  • 52 Perfect J R, Dodds Ashley E, Drew R. Design of aerosolized amphotericin b formulations for prophylaxis trials among lung transplant recipients.  Clin Infect Dis. 2004;  39 (Suppl 4) S207-S210
  • 53 Borro J M, Solé A, de la Torre M et al.. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation.  Transplant Proc. 2008;  40 (9) 3090-3093
  • 54 Palmer S M, Drew R H, Whitehouse J D et al.. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients.  Transplantation. 2001;  72 (3) 545-548
  • 55 Reichenspurner H, Gamberg P, Nitschke M et al.. Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis.  Transplant Proc. 1997;  29 (1-2) 627-628
  • 56 Drew R H, Dodds Ashley E, Benjamin Jr D K, Duane Davis R, Palmer S M, Perfect J R. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients.  Transplantation. 2004;  77 (2) 232-237
  • 57 Lowry C M, Marty F M, Vargas S O et al.. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study.  Transpl Infect Dis. 2007;  9 (2) 121-125
  • 58 Corcoran T E, Venkataramanan R, Mihelc K M et al.. Aerosol deposition of lipid complex amphotericin-B (Abelcet) in lung transplant recipients.  Am J Transplant. 2006;  6 (11) 2765-2773
  • 59 Monforte V, Ussetti P, López R et al.. Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety.  J Heart Lung Transplant. 2009;  28 (2) 170-175
  • 60 Husain S, Capitano B, Corcoran T et al.. Intrapulmonary disposition of amphotericin B after aerosolized delivery of amphotericin B lipid complex (Abelcet; ABLC) in lung transplant recipients.  Transplantation. 2010;  90 (11) 1215-1219
  • 61 Monforte V, Román A, Gavaldà J et al.. Contamination of the nebulization systems used in the prophylaxis with amphotericin B nebulized in lung transplantation.  Transplant Proc. 2005;  37 (9) 4056-4058
  • 62 Shitrit D, Ollech J E, Ollech A et al.. Itraconazole prophylaxis in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interaction.  J Heart Lung Transplant. 2005;  24 (12) 2148-2152
  • 63 Han K, Capitano B, Bies R et al.. Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients.  Antimicrob Agents Chemother. 2010;  54 (10) 4424-4431
  • 64 Cadena J, Levine D J, Angel L F et al.. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness.  Am J Transplant. 2009;  9 (9) 2085-2091
  • 65 Mattner F, Chaberny I F, Weissbrodt H et al.. [Surveillance of invasive mold infections in lung transplant recipients: effect of antimycotic prophylaxis with itraconazole and voriconazole].  Mycoses. 2005;  48 (Suppl 1) 51-55
  • 66 Mattner F, Weissbrodt H, Strueber M. Two case reports: fatal Absidia corymbifera pulmonary tract infection in the first postoperative phase of a lung transplant patient receiving voriconazole prophylaxis, and transient bronchial Absidia corymbifera colonization in a lung transplant patient.  Scand J Infect Dis. 2004;  36 (4) 312-314
  • 67 Calvo V, Borro J M, Morales P Valencia Lung Transplant Group et al. Antifungal prophylaxis during the early postoperative period of lung transplantation.  Chest. 1999;  115 (5) 1301-1304
  • 68 Eriksson M, Lemström K, Suojaranta-Ylinen R et al.. Control of early Aspergillus mortality after lung transplantation: outcome and risk factors.  Transplant Proc. 2010;  42 (10) 4459-4464
  • 69 Boehler A, Vogt P, Zollinger A, Weder W, Speich R. Prospective study of the value of transbronchial lung biopsy after lung transplantation.  Eur Respir J. 1996;  9 (4) 658-662
  • 70 Silveira F P, Husain S. Fungal infections in lung transplant recipients.  Curr Opin Pulm Med. 2008;  14 (3) 211-218

Robin K AveryM.D. 

Department of Infectious Disease, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University

9500 Euclid Ave., Desk G-21, Cleveland OH 44195

Email: averyr@ccf.org

    >